2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T8af,Patient and caregiver values and preferences should inform clinical management. An update to the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology's Joint Task Force on Practice Parameters guidelines on chronic urticaria (CU) plans to incorporate them; however, a systematic review of evidence on the values and preferences of patients with CU and their caregivers has not been previously available. To synthesize patient and caregiver values and preferences regarding CU treatment options. A systematic search was conducted of MEDLINE, Embase, PsycINFO, and CINAHL databases, from inception to May 15, 2025, for studies addressing patient and/or caregiver values and preferences for CU management. Paired reviewers independently screened studies, extracted data, and assessed risk of bias. Thematic and inductive content analysis was used to qualitatively synthesize findings and certainty of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative Research approach. The search resulted in 18 studies addressing the values and preferences among 28 497 participants. Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions. Low certainty evidence suggested that patients accepted minor feasibility burdens for rapid and sustained symptom relief but prioritized safety and tolerability as the risk or severity of adverse effects (eg, kidney injury, vomiting) increased. This systematic review suggests that patients with CU place high value on immediate and sustained hive, itch, and swelling relief, particularly long-term symptom-free periods, but may shift to prioritizing avoiding harms and burdens as the risk and severity of adverse effects increases. These findings may serve as a resource to improve the trustworthiness of recommendations and inform future CU management and research.31:Taa0,ImportancePatient and caregiver values and preferences should inform clinical management. An update to the American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology’s Joint Task Force on Practice Parameters guidelines on chronic urticaria (CU) plans to incorporate them; however, a systematic review of evidence on the values and preferences of patients with CU and their caregivers has not been previously available.ObjectiveTo synthesize patient and caregiver values and preferences regarding CU treatment options.Evidence ReviewA systematic search was conducted of MEDLINE, Embase, PsycINFO, and CINAHL databases, from inception to May 15, 2025, for studies addressing patient and/or caregiver values and preferences for CU management. Paired reviewers independently screened studies, extracted data, and assessed risk of bias. Thematic and inductive content analysis was used to qualitatively synthesize findings and certainty of evidence was rated per the Grading of Recommendations Assessment, Development and Evaluation−Confidence in the Evidence from Reviews of Qualitative Research approach.FindingsThe search resulted in 18 studies addressing the values and preferences among 28 497 participants. Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage—oral or topical treatments were favored over injections, with the least favored being infusions. Low certainty evidence suggested that patients accepted minor feasibility burdens for rapid and sustained symptom relief but prioritized safety and tolerability as the risk or severity of adverse effects (eg, kidney injury, vomiting) increased.Conclusions and RelevanceThis systematic review suggests that patients with CU place high value on immediate and sustained hive, itch, and swelling relief, particularly long-term symptom-free periods, but may shift to prioritizing avoiding harms and burdens as the risk and severity of adverse effects increases. These findings may serve as a resource to improve the trustworthiness of recommendations and inform future CU management and research.32:T467,The long-term complications of coronavirus disease 2019 (COVID-19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection. Only participants confirmed by real-time reverse transcription-polymerase chain reaction tests to have COVID-19 were enrolled in the COVID-19 group. The matched cohort without COVID-19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID-19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non-infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID-19 cohort, even after multivariable adjustment for potential confounders. COVID-19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.33:T4b1,AbstractThe long‐term complications of coronavirus disease 2019 (COVID‐19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection. Only participants confirmed by real‐time reverse transcription‐polymerase chain reaction tests to have COVID‐19 were enrolled in the COVID‐19 group. The matched cohort without COVID‐19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID‐19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non‐infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID‐19 cohort, even after multivariable adjustment for potential confounders. COVID‐19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Chronic Urticaria: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Chronic Urticaria (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Chronic%20Urticaria\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Chronic Urticaria\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Chronic%20Urticaria\"}]}}"}}]],["$","$L2f",null,{"title":"Chronic Urticaria: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Chronic Urticaria with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamadermatol.2026.2043","pmid":"42714921","title":"Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.2043","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-13T06:21:42.856Z","updated_at":"2026-09-13T06:21:42.856Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"brand","value":"Xolair","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"condition","value":"Chronic Inducible Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"condition","value":"Chronic Spontaneous Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"generic","value":"omalizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"modality","value":"Anti-IgE Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"sample_size","value":"n=4516","value_numeric":4516},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"warning","value":"Age group tagged as 'adult' based on typical CU trial populations; the paper does not explicitly report age group breakdown.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"warning","value":"Drug survival for chronic inducible urticaria subtype (43–49% at 7 years) was reported from a subset of included studies; direct comparison with CSU (30%) should be interpreted with caution given potential differences in study populations.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2043","tag_type":"warning","value":"The 'practice_changing' flag reflects the actionable endotype-driven stratification findings, but evidence is from observational studies only — randomized data are lacking.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis evaluated long-term drug survival of omalizumab in chronic urticaria (CU) and identified factors associated with discontinuation, pooling data from 8 observational studies (n=4,516) with up to 7 years of follow-up.","key_result":"Median omalizumab drug survival was 3.1 years (95% CI, 2.8–3.4); mean treatment duration over 7 years was 3.75 years. Discontinuation was more often due to disease control than adverse events. Autoimmune comorbidity (mainly thyroid-related) doubled the risk of discontinuation due to lack of efficacy (HR 2.03; 95% CI, 1.20–3.41). Chronic inducible urticaria showed higher 7-year survival (43–49%) vs. chronic spontaneous urticaria alone (30%).","limitations":"All included studies were observational, limiting causal inference. Individual patient-level data were reconstructed from Kaplan-Meier curves rather than sourced directly, introducing potential reconstruction error. The analysis was limited to 8 studies, and heterogeneity in study populations and follow-up durations may affect pooled estimates.","practice_takeaway":"Patients with autoimmune comorbidities (especially thyroid disease) are at higher risk of omalizumab failure in CU — consider closer monitoring and earlier reassessment in this group. Atopic patients who discontinue are more likely doing so due to disease control, suggesting a watch-and-wait approach may be appropriate after remission."}},{"doi":"10.1159/000552771","pmid":"42545921","title":"Understanding the needs and expectations of Ukrainian refugees with allergic diseases: the UCRAID@Apulia Pilot Study","journal_title":"International Archives of Allergy and Immunology","journal_issn":"1018-2438","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1159/000552771","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-08T13:23:37.117Z","updated_at":"2026-08-08T13:23:37.117Z","tags":[{"paper_doi":"10.1159/000552771","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"brand","value":"CRUSE","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"brand","value":"MASK-Air","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"condition","value":"Allergic Rhinitis","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"condition","value":"Anxiety","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"condition","value":"Asthma","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"modality","value":"mHealth Application","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"sample_size","value":"n=53","value_numeric":53},{"paper_doi":"10.1159/000552771","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"warning","value":"Chronic urticaria and atopic dermatitis described as 'prevalent' but exact n per condition is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"warning","value":"Enrollment was very low (53/381, ~14%), so findings may reflect a self-selected, more trusting subgroup rather than the broader refugee population.","value_numeric":null},{"paper_doi":"10.1159/000552771","tag_type":"warning","value":"The study is a single-region pilot (Apulia, Italy) with no comparator group, limiting external validity.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional pilot study evaluated the feasibility of two mHealth apps (MASK-air® and CRUSE®) among adult Ukrainian refugees with asthma, allergic rhinitis, atopic dermatitis, or chronic urticaria in Apulia, Italy, from July 2023 to June 2024.","key_result":"Of 381 eligible refugees, only 53 (13.91%) enrolled — mainly deterred by mistrust and fear of reprisals. Yet 71% of enrollees used the apps for ≥5 consecutive days at 30-day follow-up, with high satisfaction; 32.1% had anxiety/depression and 17% reported pain on EQ-5D-5L.","limitations":"Very low enrollment rate (13.91%) driven by fear and distrust limits generalizability; small final sample (n=53); single-region pilot with no control group.","practice_takeaway":"mHealth tools can be feasibly adopted by refugee populations with allergic diseases, even across language barriers, but trust-building is essential before wide rollout. Clinicians should screen Ukrainian refugees for anxiety/depression alongside allergic conditions, as these were common co-occurring findings."}},{"doi":"10.1177/2151321x261470202","pmid":"42473855","title":"Clinical Follow-Up, Etiology, and Predictors of Progression to Chronic Urticaria in Children with Acute Urticaria: A Guideline-Based Study","journal_title":"Pediatric Allergy, Immunology, and Pulmonology","journal_issn":"2151-321X","published_at":"2026-07-20T00:00:00.000Z","url":"https://doi.org/10.1177/2151321x261470202","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-24T13:38:23.101Z","updated_at":"2026-07-24T13:38:23.101Z","tags":[{"paper_doi":"10.1177/2151321x261470202","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"condition","value":"Acute Urticaria","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"modality","value":"Antihistamine","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"sample_size","value":"n=210","value_numeric":210},{"paper_doi":"10.1177/2151321x261470202","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"warning","value":"Follow-up duration (median 5 months) is relatively short; the true rate of progression to chronic urticaria may be underestimated.","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"warning","value":"Study is single-center, which may limit generalizability to different geographic or healthcare settings.","value_numeric":null},{"paper_doi":"10.1177/2151321x261470202","tag_type":"warning","value":"The absence of confirmed drug-induced urticaria is notable and may reflect referral patterns or local prescribing practices rather than a true epidemiologic finding.","value_numeric":null}],"summaries":{"what_studied":"This prospective cohort study evaluated etiologic causes, guideline adherence, and predictors of progression from acute urticaria (AU) to chronic urticaria (CU) in 210 children (median age 5.4 years) followed for a median of 5 months at a single center.","key_result":"95.2% achieved complete remission with standard antihistamine therapy; only 4.8% progressed to CU. Urticaria lasting >7 days (OR 14.1, 95% CI 2.62–75.73) and physical stimuli as trigger (OR 22.8, 95% CI 2.95–177.19) were independent predictors of chronicity. Infections were the leading confirmed cause (55.2%); 65.7% of patients required no diagnostic testing.","limitations":"Single-center design limits generalizability. Median follow-up was only 5 months (range 1.5–14), which may be too short to capture all cases progressing to CU. No drug-induced urticaria was confirmed, which may reflect population or ascertainment bias.","practice_takeaway":"For most children with acute urticaria, guideline-based management with antihistamines and minimal testing is sufficient. Flag patients whose hives last more than 7 days or are triggered by physical stimuli — they need closer follow-up given a significantly higher risk of progressing to chronic urticaria."}},{"doi":"10.1007/s13555-026-01844-5","pmid":"42412369","title":"Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-07-07T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01844-5","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-17T13:24:07.608Z","updated_at":"2026-07-17T13:24:07.608Z","tags":[{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"condition","value":"Chronic Prurigo","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"condition","value":"Chronic Pruritus","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"sample_size","value":"n=522","value_numeric":522},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"warning","value":"The correlation range for itch-related factors vs. 5PLQ is reported as 'r=515–0.603' in the abstract, likely a typographic error for r=0.515–0.603; this is reflected correctly in the summary.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the finding that peak itch (WI-NRS) — widely used in clinical trials — did not significantly mediate QoL, while average itch and daily duration did; clinicians may wish to interpret this cautiously given the cross-sectional design.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01844-5","tag_type":"warning","value":"The study received unrestricted funding from Novartis Pharma GmbH; multiple authors report conflicts of interest with pharmaceutical companies, though funders had no role in data analysis or reporting.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional study (n=522 adults; median age 56 years) examined how itch-related factors — average itch intensity (AI-NRS), daily itch duration, scratching frequency, and sleep disturbance — mediate the relationship between clinician-assessed disease severity and quality of life (QoL) impairment (measured by 5PLQ) in patients with atopic dermatitis, psoriasis, chronic prurigo, or chronic urticaria, recruited across Germany between 2018 and 2020.","key_result":"Disease severity correlated only weakly with QoL (r=0.201), while itch-related factors correlated strongly (r=0.515–0.603). Mediation analyses showed the severity–QoL link was partially mediated by daily itch duration (indirect β=0.270, p<0.001), sleep disturbance (indirect β=0.235, p=0.006), scratching frequency (indirect β=0.205, p=0.010), and average itch intensity (indirect β=0.168, p=0.049); peak itch intensity (WI-NRS) did not mediate significantly.","limitations":"- Disease severity was harmonized into a single 0–3 scale across four conditions; CU severity used a non-validated IGA, which may reduce comparability.\n- Cross-sectional design prevents causal inference, only establishing mediation paths at a single time point.\n- Only adults were included, limiting generalizability to pediatric patients.","practice_takeaway":"When managing chronic pruritic skin diseases, assess all four dimensions of itch — daily duration, sleep disruption, scratching frequency, and average (not just peak) itch intensity — as these drive QoL impairment more than skin severity scores alone. Targeting these specific itch dimensions with therapy may improve patient outcomes beyond what standard severity-based assessments capture."}},{"doi":"10.1001/jamadermatol.2026.1901","pmid":"42340685","title":"Progression From Acute to Chronic Urticaria","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1901","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-01T13:27:02.885Z","updated_at":"2026-07-01T13:27:02.885Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"condition","value":"Acute Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"sample_size","value":"n=52564","value_numeric":52564},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"warning","value":"Impact flag 'practice_changing' applied because the review explicitly contradicts a common clinical rationale for aggressive acute-phase treatment (corticosteroids to prevent chronicity).","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"warning","value":"Sex distribution of included patients is not reported in the abstract; sex tag was omitted.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1901","tag_type":"warning","value":"The wide progression rate range (5.8%–36.0%) likely reflects heterogeneous study populations and follow-up periods rather than true biological variability — clinicians should interpret any single rate cautiously.","value_numeric":null}],"summaries":{"what_studied":"This systematic review evaluated clinical, laboratory, and treatment-related factors associated with progression from acute urticaria (AU) to chronic urticaria (CU), searching MEDLINE, Embase, and Web of Science through December 31, 2025.","key_result":"Across 16 studies (n=52,564), progression rates ranged from 5.8% to 36.0%; no single clinical or laboratory marker — including disease severity, angioedema, IgE levels, eosinophil counts, autoantibodies, or systemic corticosteroid use — was consistently associated with progression to CU.","limitations":"- High methodologic heterogeneity across studies with varying follow-up durations and outcome definitions.\n- Moderate to high risk of bias in included studies; higher progression rates may reflect selection bias in tertiary centers.\n- Qualitative synthesis only — meta-analysis was not feasible due to heterogeneity.","practice_takeaway":"Do not use aggressive treatment (e.g., systemic corticosteroids) during acute urticaria solely to prevent chronicity — current evidence does not support this approach. Structured clinical follow-up remains the best tool while better prognostic markers are awaited."}},{"doi":"10.1016/j.waojou.2026.101398","pmid":null,"title":"Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria — Insights from the UCARE/ADCARE PROMUSE study","journal_title":"World Allergy Organization Journal","journal_issn":"1939-4551","published_at":"2026-06-05T00:00:00.000Z","url":"https://doi.org/10.1016/j.waojou.2026.101398","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-06-13T15:34:43.357Z","updated_at":"2026-06-13T15:34:43.357Z","tags":[{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"study_design","value":"Survey Study","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"warning","value":"Only the paper's metadata (title, DOI, journal, publication date) was provided — no abstract, methods, results, or full text were available. All structured fields are inferred from the title alone and should be treated as provisional.","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"warning","value":"Study design, sample size, sex, level of evidence, and key numeric results cannot be determined without the full text.","value_numeric":null},{"paper_doi":"10.1016/j.waojou.2026.101398","tag_type":"warning","value":"The 'PROMUSE' acronym and the UCARE/ADCARE network context suggest a multinational or registry-based study, but this could not be confirmed from the available information.","value_numeric":null}],"summaries":{"what_studied":"The UCARE/ADCARE PROMUSE study investigated why physicians underuse patient-reported outcomes (PROs) in the clinical management of atopic dermatitis (AD) and chronic urticaria (CU), examining barriers and facilitators to PRO implementation in practice.","limitations":"Only the DOI and metadata are available — full text, sample size, results, and methodology could not be reviewed, so specific findings, numbers, and study design details cannot be confirmed.","practice_takeaway":"Identifying barriers to PRO use in AD and CU may help clinicians integrate patient-centered tools more consistently into routine care; however, specific actionable findings cannot be confirmed without access to the full text."}},{"doi":"10.1016/j.jaip.2026.05.031","pmid":"42250644","title":"Second-generation H1-antihistamines do not alter dementia risk in type 2 inflammatory diseases: A target trial emulation using real-world data","journal_title":"The Journal of Allergy and Clinical Immunology: In Practice","journal_issn":"2213-2198","published_at":"2026-06-05T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaip.2026.05.031","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-13T15:34:41.021Z","updated_at":"2026-06-13T15:34:41.021Z","tags":[{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"condition","value":"Allergic Rhinitis","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"condition","value":"Chronic Sinusitis","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"modality","value":"First-Generation H1-Antihistamine","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"modality","value":"Intranasal Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"modality","value":"Second-Generation H1-Antihistamine","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"sample_size","value":"n=106651","value_numeric":106651},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"study_design","value":"Target Trial Emulation / Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"warning","value":"Specific sgAH drug names and brands are not reported in the abstract; no generic or brand tags could be assigned.","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"warning","value":"Study design is labeled 'target trial emulation' but is fundamentally retrospective/observational; level of evidence assigned as 3 reflects this.","value_numeric":null},{"paper_doi":"10.1016/j.jaip.2026.05.031","tag_type":"warning","value":"The sample size of n=106,651 is an approximation summing the three matched patient cohorts (48,238 + 21,611 + 36,802); each had equal-sized control groups, so total participants across all arms may be roughly double this figure — the abstract does not provide a single consolidated total.","value_numeric":null}],"summaries":{"what_studied":"This target trial emulation used real-world EHR data (TriNetX network) to assess whether second-generation H1-antihistamines (sgAH) increase dementia risk over 5 years in patients aged ≥50 with chronic urticaria (CU), chronic sinusitis (CS), or allergic rhinitis (AR), compared to first-generation antihistamines (fgAH) or non-antihistamine alternatives (intranasal or oral steroids).","key_result":"After propensity-score matching across 38 covariates, no increased dementia risk was found for sgAH vs. any comparator in CU (n=48,238), CS (n=21,611), or AR (n=36,802) cohorts. Intranasal steroid use in AR patients was associated with a slight *decrease* in dementia risk (p=0.007).","limitations":"- Observational design limits causal inference despite propensity-score matching.\n- Reliance on EHR data may introduce coding inaccuracies and unmeasured confounders (e.g., dose, duration, adherence).\n- Only patients aged ≥50 were studied, limiting generalizability to younger populations.","practice_takeaway":"Clinicians can reassure patients that sgAH use for type 2 inflammatory diseases does not appear to raise dementia risk compared to fgAH or steroids. The slight dementia risk reduction seen with intranasal steroids in AR warrants further study but should not yet change prescribing patterns."}},{"doi":"10.1001/jamadermatol.2025.3663","pmid":"41060663","title":"Patient Values and Preferences in Chronic Urticaria Treatment","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-10-08T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.3663","source_score":13,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-13","doi":"10.1001/jamadermatol.2025.3663","days":"14","issn":"2168-6068","rank":"6","field":"Clinical Medicine","score":"13","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.3663","title":"Patient Values and Preferences in Chronic Urticaria Treatment: A Systematic Review.","journal":"JAMA dermatology","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41060663","conclusions":"","publication_date":"2025-10-08T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.3663","URL":"https://doi.org/10.1001/jamadermatol.2025.3663","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2839732/jamadermatology_chu_2025_rv_250004_1759870969.80788.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Patient Values and Preferences in Chronic Urticaria Treatment"],"author":[{"given":"Xiajing","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Javeria","family":"Mubasher","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Alexandro W. L.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Paul","family":"Oykhman","sequence":"additional","affiliation":[{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Gordon H.","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Anja Fog","family":"Heen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway"}]},{"given":"David A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Allergy and Immunology, The University of Texas Southwestern Medical Center, Dallas"}]},{"given":"David M.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Diane R.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Sciences University, Portland"}]},{"given":"Eric T.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}]},{"given":"Javed","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Southern California Permanente Medical Group, Los Angeles"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rochester Medical Center, Rochester, New York"}]},{"given":"Moshe","family":"Ben-Shoshan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Allergy, Immunology and Dermatology, McGill University, Montreal, Quebec, Canada"}]},{"given":"Sameer K.","family":"Mathur","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Emily F.","family":"Cole","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}]},{"given":"Jeffrey","family":"Chan","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Southlake Regional Health Centre, Newmarket, Ontario, Canada"}]},{"given":"Kathryn E.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Florida, Gainesville"}]},{"given":"Kathryn P.","family":"Trayes","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania"}]},{"given":"Lauren","family":"Runyon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Allergy and Immunology, The University of Texas Southwestern Medical Center, Dallas"}]},{"given":"Paul","family":"Tran","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine, Phoenix Children’s Hospital, Phoenix"}]},{"given":"Rachel N.","family":"Asiniwasis","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of Saskatchewan, Regina, Saskatchewan, Canada"}]},{"given":"Donna D.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Allergy & Asthma Network, Fairfax, Virginia"}]},{"given":"Sanaz","family":"Eftekhari","sequence":"additional","affiliation":[{"name":"Asthma and Allergy Foundation of America, Arlington, Virginia"}]},{"given":"Tonya","family":"Winders","sequence":"additional","affiliation":[{"name":"Global Allergy & Airways Patient Platform, Vienna, Austria"}]},{"given":"Jamie","family":"Tattrie","sequence":"additional","affiliation":[{"name":"Port Alberni, British Columbia, Canada"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio"}]},{"given":"Sarbjit S.","family":"Saini","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}]},{"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"The Research Institute of St Joe’s Hamilton, Hamilton, Ontario, Canada"}]}],"issued":{"date-parts":[[2025,10,8]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-10-08T15:00:53Z","timestamp":1759935653000,"date-parts":[[2025,10,8]]},"indexed":{"date-time":"2025-10-08T15:40:21Z","timestamp":1759938021860,"date-parts":[[2025,10,8]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2839732"}},"subtitle":["A Systematic Review"],"deposited":{"date-time":"2025-10-08T15:00:55Z","timestamp":1759935655000,"date-parts":[[2025,10,8]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,8]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaip.2023.06.033","key":"drv250004r1","year":"2023","issue":"8","author":"Bernstein","volume":"11","first-page":"2251","unstructured":null,"article-title":"Chronic urticaria and angioedema: masqueraders and misdiagnoses.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2014.02.036","key":"drv250004r2","year":"2014","issue":"5","author":"Bernstein","volume":"133","first-page":"1270","unstructured":null,"article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMra2120166","key":"drv250004r3","year":"2022","issue":"9","author":"Lang","volume":"387","first-page":"824","unstructured":null,"article-title":"Chronic Urticaria.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.10.004","key":"drv250004r4","year":"2022","issue":"6","author":"Zuberbier","volume":"150","first-page":"1249","unstructured":null,"article-title":"Chronic spontaneous urticaria guidelines: what is new?","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2020.03.030","key":"drv250004r5","year":"2020","issue":"6","author":"Saini","volume":"8","first-page":"1866","unstructured":null,"article-title":"Urticaria and angioedema across the ages.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2021.09.035","key":"drv250004r6","year":"2021","issue":"12","author":"Chu","volume":"9","first-page":"4221","unstructured":null,"article-title":"Translating evidence to optimize patient care using GRADE.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2022.06.017","key":"drv250004r7","year":"2022","issue":"11","author":"Agarwal","volume":"10","first-page":"2875","unstructured":null,"article-title":"Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.6045","key":"drv250004r8","year":"2023","issue":"3","author":"Maleki-Yazdi","volume":"159","first-page":"320","unstructured":null,"article-title":"Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12955-017-0621-0","key":"drv250004r9","year":"2017","issue":"1","author":"Zhang","volume":"15","first-page":"52","unstructured":null,"article-title":"Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach.","journal-title":"Health Qual Life Outcomes","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15090","key":"drv250004r10","year":"2022","issue":"3","author":"Zuberbier","volume":"77","first-page":"734","unstructured":null,"article-title":"The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2024.06.003","key":"drv250004r11","year":"2024","issue":"4","author":"Chu","volume":"133","first-page":"437","unstructured":null,"article-title":"Topical corticosteroids for hives and itch (urticaria): systematic review and Bayesian meta-analysis of randomized trials.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2024.05.026","key":"drv250004r12","year":"2024","issue":"4","author":"Rayner","volume":"154","first-page":"996","unstructured":null,"article-title":"Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2024.04.016","key":"drv250004r13","year":"2024","issue":"7","author":"Chu","volume":"12","first-page":"1879","unstructured":null,"article-title":"Efficacy and safety of systemic corticosteroids for urticaria: a systematic review and meta-analysis of randomized clinical trials.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.n71","key":"drv250004r14","year":"2021","issue":"71","author":"Page","volume":"372","first-page":"n71","unstructured":null,"article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2016.01.002","key":"drv250004r16","year":"2016","issue":null,"author":"Jelicic Kadic","volume":"74","first-page":"119","unstructured":null,"article-title":"Extracting data from figures with software was faster, with higher interrater reliability than manual extraction.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjopen-2021-050831","key":"drv250004r17","year":"2021","issue":"9","author":"Zeng","volume":"11","first-page":null,"unstructured":null,"article-title":"Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review.","journal-title":"BMJ Open","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijnurstu.2016.03.010","key":"drv250004r18","year":"2016","issue":null,"author":"Karimi","volume":"59","first-page":"89","unstructured":null,"article-title":"How do patients’ values influence heart failure self-care decision-making?: A mixed-methods systematic review.","journal-title":"Int J Nurs Stud","doi-asserted-by":"publisher"},{"DOI":"10.7326/M19-1326","key":"drv250004r19","year":"2019","issue":"10","author":"Valli","volume":"171","first-page":"742","unstructured":null,"article-title":"Health-related values and preferences regarding meat consumption: a mixed-methods systematic review.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11135-017-0533-4","key":"drv250004r20","year":"2018","issue":"4","author":"DeCastellarnau","volume":"52","first-page":"1523","unstructured":null,"article-title":"A classification of response scale characteristics that affect data quality: a literature review.","journal-title":"Qual Quant","doi-asserted-by":"publisher"},{"DOI":"10.1136/heartjnl-2020-318334","key":"drv250004r21","year":"2021","issue":"16","author":"Heen","volume":"107","first-page":"1289","unstructured":null,"article-title":"Patient values and preferences on valve replacement for aortic stenosis: a systematic review.","journal-title":"Heart","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2020.10.002","key":"drv250004r22","year":"2021","issue":null,"author":"Heen","volume":"129","first-page":"104","unstructured":null,"article-title":"A framework for practical issues was developed to inform shared decision-making tools and clinical guidelines.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-021-02321-z","key":"drv250004r23","year":"2023","issue":"1","author":"de Wijs","volume":"315","first-page":"75","unstructured":null,"article-title":"Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study.","journal-title":"Arch Dermatol Res","doi-asserted-by":"publisher"},{"DOI":"10.1186/1471-2288-8-45","key":"drv250004r24","year":"2008","issue":null,"author":"Thomas","volume":"8","first-page":"45","unstructured":null,"article-title":"Methods for the thematic synthesis of qualitative research in systematic reviews.","journal-title":"BMC Med Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjopen-2020-041229","key":"drv250004r25","year":"2020","issue":"11","author":"Clement","volume":"10","first-page":null,"unstructured":null,"article-title":"Parents and GPs’ understandings and beliefs about food allergy testing in children with eczema: qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial.","journal-title":"BMJ Open","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2018.01.013","key":"drv250004r26","year":"2019","issue":null,"author":"Zhang","volume":"111","first-page":"94","unstructured":null,"article-title":"GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0694-5","key":"drv250004r27","year":"2018","issue":null,"author":"Booth","volume":"13","first-page":"12","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 7: understanding the potential impacts of dissemination bias.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0691-8","key":"drv250004r28","year":"2018","issue":null,"author":"Colvin","volume":"13","first-page":"13","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 4: how to assess coherence.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0692-7","key":"drv250004r29","year":"2018","issue":null,"author":"Glenton","volume":"13","first-page":"14","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 5: how to assess adequacy of data.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0689-2","key":"drv250004r30","year":"2018","issue":null,"author":"Lewin","volume":"13","first-page":"10","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 2: how to make an overall CERQual assessment of confidence and create a summary of qualitative findings table.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0688-3","key":"drv250004r31","year":"2018","issue":null,"author":"Lewin","volume":"13","first-page":"2","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0690-9","key":"drv250004r32","year":"2018","issue":null,"author":"Munthe-Kaas","volume":"13","first-page":"9","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 3: how to assess methodological limitations.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13012-017-0693-6","key":"drv250004r33","year":"2018","issue":null,"author":"Noyes","volume":"13","first-page":"4","unstructured":null,"article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 6: how to assess relevance of the data.","journal-title":"Implement Sci","doi-asserted-by":"publisher"},{"DOI":null,"key":"drv250004r34","year":"2019","issue":"4","author":"Sahu","volume":"29","first-page":"384","unstructured":null,"article-title":"Do traditional beliefs about urticaria affect patient satisfaction in South India? – A knowledge, attitude and practices survey.","journal-title":"J Pak Assoc Dermatol","doi-asserted-by":null},{"DOI":"10.1080/09546634.2018.1476651","key":"drv250004r35","year":"2019","issue":"2","author":"Akdogan","volume":"30","first-page":"183","unstructured":null,"article-title":"Educational level and job status are the most important factors affecting compliance with oral antihistamine therapy for patients with chronic urticaria.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.11.298","key":"drv250004r36","year":"2024","issue":"2","author":"Babalola","volume":"153","first-page":"AB89","unstructured":null,"article-title":"Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.4077/CJP.2010.AMK007","key":"drv250004r37","year":"2010","issue":"4","author":"Fang","volume":"53","first-page":"199","unstructured":null,"article-title":"An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients.","journal-title":"Chin J Physiol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.waojou.2021.100587","key":"drv250004r38","year":"2021","issue":"10","author":"King","volume":"14","first-page":null,"unstructured":null,"article-title":"Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective.","journal-title":"World Allergy Organ J","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14203","key":"drv250004r39","year":"2016","issue":"4","author":"Maurer","volume":"174","first-page":"892","unstructured":null,"article-title":"ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1398-9995.2008.01853.x","key":"drv250004r40","year":"2009","issue":"4","author":"Maurer","volume":"64","first-page":"581","unstructured":null,"article-title":"Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14415","key":"drv250004r41","year":"2021","issue":"6","author":"Rönsch","volume":"19","first-page":"833","unstructured":null,"article-title":"Treatment satisfaction in chronic urticaria during guideline-based therapy.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2020.3763","key":"drv250004r42","year":"2020","issue":"3","author":"Sommer","volume":"30","first-page":"259","unstructured":null,"article-title":"Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria.","journal-title":"Eur J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2165/11314870-000000000-00000","key":"drv250004r43","year":"2009","issue":"3","author":"Stull","volume":"2","first-page":"151","unstructured":null,"article-title":"Use of, satisfaction with, and willingness to switch prescription and over-the-counter treatments for chronic urticaria: an online survey.","journal-title":"Patient","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00537-5","key":"drv250004r44","year":"2021","issue":"3","author":"Wagner","volume":"11","first-page":"1027","unstructured":null,"article-title":"Patients with Chronic Urticaria Remain Largely Undertreated: results from the DERMLINE Online Survey.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1080/13548506.2022.2029914","key":"drv250004r45","year":"2023","issue":"2","author":"Yong","volume":"28","first-page":"324","unstructured":null,"article-title":"Psychological well-being, quality of life and patient satisfaction among adults with chronic spontaneous urticaria in a multi-ethnic Asian population.","journal-title":"Psychol Health Med","doi-asserted-by":"publisher"},{"DOI":"10.32932/rpia.2023.04.109","key":"drv250004r46","year":"2023","issue":null,"author":"Bernardino","volume":null,"first-page":"31","unstructured":null,"article-title":"Autoadministração de omalizumab na urticária crónica espontânea – Estudo observacional num centro UCARE.","journal-title":"Rev Port Imunoalergol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40271-024-00725-3","key":"drv250004r47","year":"2025","issue":"2","author":"Giménez-Arnau","volume":"18","first-page":"173","unstructured":null,"article-title":"Assessing preferences of patients with chronic spontaneous urticaria for injectable treatment profiles.","journal-title":"Patient","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2019.1591580","key":"drv250004r48","year":"2020","issue":"4","author":"Coyle","volume":"31","first-page":"352","unstructured":null,"article-title":"Patient experiences of using Chinese herbal medicine for psoriasis vulgaris and chronic urticaria: a qualitative study.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1136/ejhpharm-2019-001914","key":"drv250004r49","year":"2020","issue":"6","author":"Denman","volume":"27","first-page":"367","unstructured":null,"article-title":"Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.","journal-title":"Eur J Hosp Pharm","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3282","key":"drv250004r50","year":"2019","issue":"12","author":"Goldstein","volume":"99","first-page":"1091","unstructured":null,"article-title":"Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jval.2021.11.1193","key":"drv250004r51","year":"2022","issue":"1","author":"Maurer","volume":"25","first-page":"S244","unstructured":null,"article-title":"Understanding the impact of chronic spontaneous urticaria (CSU) and what is most important to patients 2014; results from qualitative patient interviews.","journal-title":"Value Health","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2024-081903","key":"drv250004r52","year":"2025","issue":null,"author":"Guyatt","volume":"389","first-page":null,"unstructured":null,"article-title":"Core GRADE 1: overview of the Core GRADE approach.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01348-8","key":"drv250004r53","year":"2025","issue":"3","author":"Weller","volume":"15","first-page":"747","unstructured":null,"article-title":"Urticaria voices: real-world experience of patients living with chronic spontaneous urticaria.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.12.430","key":"drv250004r54","year":"2023","issue":"2","author":"Drexel","volume":"151","first-page":"AB138","unstructured":null,"article-title":"Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-023-02724-6","key":"drv250004r55","year":"2024","issue":"1","author":"Maurer","volume":"41","first-page":"14","unstructured":null,"article-title":"A Patient charter for chronic urticaria.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2023.11.009","key":"drv250004r56","year":"2024","issue":"3","author":"Chu","volume":"132","first-page":"274","unstructured":null,"article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.anai.2012.11.022","key":"drv250004r57","year":"2013","issue":"2","author":"Song","volume":"110","first-page":"113","unstructured":null,"article-title":"Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.","journal-title":"Ann Allergy Asthma Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000530494","key":"drv250004r58","year":"2023","issue":"10","author":"Narváez-Fernández","volume":"184","first-page":"1003","unstructured":null,"article-title":"Long-term omalizumab in elderly patients with chronic urticaria: is it a safe therapy?","journal-title":"Int Arch Allergy Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2025.06.004","key":"drv250004r59","year":"2025","issue":null,"author":"Chu","volume":null,"first-page":null,"unstructured":null,"article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.2056","key":"drv250004r60","year":"2024","issue":"9","author":"Soegiharto","volume":"160","first-page":"927","unstructured":null,"article-title":"Multinational drug survival study of omalizumab in patients with chronic urticaria and potential predictors for discontinuation.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12911-025-02945-5","key":"drv250004r61","year":"2025","issue":"1","author":"Fusiak","volume":"25","first-page":"109","unstructured":null,"article-title":"Practical applications of methods to incorporate patient preferences into medical decision models: a scoping review.","journal-title":"BMC Med Inform Decis Mak","doi-asserted-by":"publisher"},{"DOI":null,"key":"drv250004r15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Mark? M, Baurzhan? M, Tobias? W, Alexander? W, Bas? VS. Badshah400. markummitchell/engauge-digitizer: Nonrelease.? Zenodo; 2020.","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":61,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,8]]},"references-count":61,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.3663","is_oa":false,"title":"Patient Values and Preferences in Chronic Urticaria Treatment","updated":"2025-10-09T00:28:14+00:00","published_date":"2025-10-08","best_oa_location":null}},"created_at":"2025-10-14T07:02:46.938Z","updated_at":"2025-10-19T07:07:31.491Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"sample_size","value":"n=28,497","value_numeric":28497},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"warning","value":"Age, sex distribution, and specific treatments are not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"warning","value":"Only the abstract was available; full text may provide additional detail on study characteristics and bias.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3663","tag_type":"warning","value":"This is a qualitative evidence synthesis, not a quantitative meta-analysis of efficacy or safety.","value_numeric":null}],"summaries":{"what_studied":"Systematic review of 18 studies (n=28,497) synthesizing patient and caregiver values and preferences for chronic urticaria treatment; databases were searched from inception to May 15, 2025, and findings were synthesized using thematic analysis with GRADE-CERQual ratings.","key_result":"Moderate-certainty evidence indicates patients value rapid improvement (about 2 days to 2 weeks), long-term effectiveness, and easy-to-use, self-managed treatments—favoring oral or topical options over injections, with infusions least favored. Low-certainty evidence suggests patients may accept minor burdens for rapid and sustained relief but shift to prioritizing safety and tolerability as the risk or severity of adverse effects (e.g., kidney injury, vomiting) increases.","limitations":"Certainty was low for evidence about trade-offs between accepting feasibility burdens and prioritizing safety/tolerability.","practice_takeaway":"In CU care, emphasize options that deliver fast (within 2 days to 2 weeks) and durable relief with simple self-management, favoring oral or topical routes when reasonable. Discuss adverse effect risks clearly, as higher risk or severity can shift patients toward prioritizing safety over convenience."}},{"doi":"10.1111/1346-8138.17600","pmid":"39737861","title":"Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection: A nationwide population‐based study","journal_title":"The Journal of Dermatology","journal_issn":"0385-2407","published_at":"2024-12-31T00:00:00.000Z","url":"https://doi.org/10.1111/1346-8138.17600","source_score":75,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-01-16","doi":"10.1111/1346-8138.17600","days":"30","issn":"0385-2407","rank":"5","field":"Clinical Medicine","score":"75","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/1346-8138.17600","title":"Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection: A nationwide population-based study.","journal":"The Journal of dermatology","methods":"","results":"","abstract":"$32","keywords":["COVID‐19","alopecia areata","herpes zoster","urticaria","vitiligo"],"pubmed_id":"39737861","conclusions":"","publication_date":"2024-12-31T00:00:00"},"crossref":{"DOI":"10.1111/1346-8138.17600","URL":"https://doi.org/10.1111/1346-8138.17600","ISSN":["0385-2407","1346-8138"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.17600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"499-504","type":"journal-article","issue":"3","score":1,"title":["Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection: A nationwide population‐based study"],"author":[{"given":"Min Hee","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Otolaryngology, and Dermatology, Kyung Hee University College of Korean Medicine Kyung Hee University Hospital at Gangdong Seoul Republic of Korea"}]}],"funder":[{"id":[{"id":"10.13039/501100003725","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100003725","name":"National Research Foundation of Korea","award":["RS‐2024‐00409969"],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2024,12,31]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"52","archive":["Portico"],"created":{"date-time":"2024-12-31T12:14:38Z","timestamp":1735647278000,"date-parts":[[2024,12,31]]},"indexed":{"date-time":"2025-09-09T22:25:03Z","timestamp":1757456703627,"date-parts":[[2025,9,9]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000,"date-parts":[[2024,12,31]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17600"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2024-09-23"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2024-12-12"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2024-12-31"}],"deposited":{"date-time":"2025-05-19T17:23:29Z","timestamp":1747675409000,"date-parts":[[2025,5,19]]},"issn-type":[{"type":"print","value":"0385-2407"},{"type":"electronic","value":"1346-8138"}],"published":{"date-parts":[[2024,12,31]]},"publisher":"Wiley","reference":[{"DOI":"10.1056/NEJMoa2002032","key":"e_1_2_9_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jocd.15477","key":"e_1_2_9_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pmed.1004052","key":"e_1_2_9_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.36120","key":"e_1_2_9_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.12997/jla.2022.11.2.103","key":"e_1_2_9_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_7_1","year":"2017","issue":null,"author":"Cheol Seong S","volume":"46","first-page":"799","unstructured":null,"article-title":"Data resource profile: the national health information database of the National Health Insurance Service in South Korea","journal-title":"Int J Epidemiol","doi-asserted-by":null},{"DOI":"10.4093/dmj.2020.0008","key":"e_1_2_9_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.alit.2018.05.011","key":"e_1_2_9_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18247","key":"e_1_2_9_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.01.046","key":"e_1_2_9_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3346/jkms.2014.29.12.1706","key":"e_1_2_9_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000505911","key":"e_1_2_9_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/all.13414","key":"e_1_2_9_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.iac.2013.09.010","key":"e_1_2_9_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.04.010","key":"e_1_2_9_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.16799","key":"e_1_2_9_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/all.14687","key":"e_1_2_9_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.07.019","key":"e_1_2_9_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_20_1","year":"2023","issue":null,"author":"Kasmikha LC","volume":"15","first-page":null,"unstructured":null,"article-title":"Vitiligo following COVID‐19 vaccination and primary infection: a case report and systematic review","journal-title":"Cureus","doi-asserted-by":null},{"DOI":"10.3389/fmed.2021.758069","key":"e_1_2_9_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/jmv.28745","key":"e_1_2_9_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/v14071415","key":"e_1_2_9_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-022-22711-1","key":"e_1_2_9_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)30183-5","key":"e_1_2_9_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2020.01823","key":"e_1_2_9_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.17148","key":"e_1_2_9_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18008","key":"e_1_2_9_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0227909","key":"e_1_2_9_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms241411711","key":"e_1_2_9_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/biology12010123","key":"e_1_2_9_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cellimm.2009.03.007","key":"e_1_2_9_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s15010-021-01714-6","key":"e_1_2_9_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.mayocp.2021.05.029","key":"e_1_2_9_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms21217873","key":"e_1_2_9_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10654-013-9873-0","key":"e_1_2_9_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/1346-8138.17600"],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,3]]},"reference-count":35,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2024,12,31]]},"references-count":35,"short-container-title":["The Journal of Dermatology"],"is-referenced-by-count":2},"unpaywall":{"doi":"10.1111/1346-8138.17600","is_oa":false,"title":"Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection: A nationwide population‐based study","updated":"2025-05-22T18:42:22+00:00","published_date":"2024-12-31","best_oa_location":null}},"created_at":"2025-09-20T05:45:10.863Z","updated_at":"2025-09-20T05:50:54.893Z","tags":[{"paper_doi":"10.1111/1346-8138.17600","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"condition","value":"Chronic Urticaria","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"condition","value":"COVID-19","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"condition","value":"Herpes Zoster","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"condition","value":"Vitiligo","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"sample_size","value":"n=9,953,178","value_numeric":9953178},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"warning","value":"Effect sizes, absolute risks, and follow-up duration are not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"warning","value":"Outcome case definitions and ascertainment methods are not detailed in the abstract.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17600","tag_type":"warning","value":"Study design specifics (prospective vs retrospective) are not specified.","value_numeric":null}],"summaries":{"what_studied":"A nationwide, population-based matched cohort in South Korea compared the incidence of chronic urticaria, vitiligo, alopecia areata, and herpes zoster after RT‑PCR–confirmed COVID‑19 versus noninfected controls (1:1; 4,976,589 per group) using Cox proportional hazards models.","limitations":"The abstract does not report follow-up duration, event rates, or hazard ratios; outcome definitions and ascertainment methods are not described.","practice_takeaway":"COVID‑19 was associated with higher rates of chronic urticaria, vitiligo, alopecia areata, and herpes zoster versus matched controls after adjustment; consider vigilance for these conditions after infection."}}],"initialOffset":9,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Chronic Urticaria"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Chronic Urticaria"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Chronic Urticaria"}}}]]

Papers